litlas
ログインアカウント作成

Francisco Cervantes

1982–2025 年に発表

129
論文数
40,700
被引用数
89
h 指数
115
i10 指数

被引用数

Francisco Cervantes の年別被引用数1979 年: 被引用 7 件1984 年: 被引用 2 件1985 年: 被引用 3 件1987 年: 被引用 5 件1988 年: 被引用 6 件1990 年: 被引用 7 件1991 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 5 件1994 年: 被引用 5 件1995 年: 被引用 4 件1996 年: 被引用 10 件1997 年: 被引用 7 件1998 年: 被引用 10 件1999 年: 被引用 15 件2000 年: 被引用 14 件2001 年: 被引用 21 件2002 年: 被引用 27 件2003 年: 被引用 74 件2004 年: 被引用 84 件2005 年: 被引用 82 件2006 年: 被引用 97 件2007 年: 被引用 182 件2008 年: 被引用 243 件2009 年: 被引用 304 件2010 年: 被引用 266 件2011 年: 被引用 327 件2012 年: 被引用 351 件2013 年: 被引用 350 件2014 年: 被引用 335 件2015 年: 被引用 407 件2016 年: 被引用 359 件2017 年: 被引用 301 件2018 年: 被引用 234 件2019 年: 被引用 928 件2020 年: 被引用 1,250 件2021 年: 被引用 1,037 件2022 年: 被引用 820 件2023 年: 被引用 527 件2024 年: 被引用 948 件2025 年: 被引用 311 件2026 年: 被引用 8 件1980〜1983 年は被引用が無いため表示していません1986 年は被引用が無いため表示していません1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,394 件、この内訳の 24.7%イタリア: 引用元論文 904 件、この内訳の 9.3%ドイツ: 引用元論文 768 件、この内訳の 7.9%イギリス: 引用元論文 715 件、この内訳の 7.4%フランス: 引用元論文 580 件、この内訳の 6%中国: 引用元論文 384 件、この内訳の 4%スペイン: 引用元論文 384 件、この内訳の 4%カナダ: 引用元論文 279 件、この内訳の 2.9%オーストラリア: 引用元論文 278 件、この内訳の 2.9%スイス: 引用元論文 276 件、この内訳の 2.8%オランダ: 引用元論文 228 件、この内訳の 2.3%日本: 引用元論文 227 件、この内訳の 2.3%
0%24.7%その他 23.5%

機関

分野

  • Medicine79.8%
  • Biochemistry, Genetics and Molecular Biology12.8%
  • Immunology and Microbiology1.8%
  • Computer Science1.2%
  • Social Sciences1.1%
  • Neuroscience0.6%
  • その他2.7%

トピック

  • Chronic Myeloid Leukemia Treatments13.3%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment12%
  • Acute Myeloid Leukemia Research9%
  • Eosinophilic Disorders and Syndromes8.2%
  • Chronic Lymphocytic Leukemia Research6.1%
  • Kruppel-like factors research4%
  • その他47.4%

共著者

全論文

検索で開く
  1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    著者: Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 被引用: 1,510

  2. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

    著者: Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, Roger J. Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah Hunter, Richard Levy, Laurent Knoops, Francisco Cervantes, Alessandro M. Vannucchi, Tiziano Barbui, Giovanni Barosi - New England Journal of Medicine 2012 被引用: 1,791

  3. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    著者: Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O’Brien, Brian Druker - New England Journal of Medicine 2017 被引用: 1,259

  4. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    著者: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 被引用: 3,481

  5. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

    著者: Animesh Pardanani, Claire Harrison, Jörge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Éric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi - JAMA Oncology 2015 被引用: 472

  6. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

    著者: Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib - Journal of Clinical Oncology 2017 被引用: 367

  7. Artificial Moral Agents: A Survey of the Current Status

    著者: José-Antonio Cervantes, Sonia López, Luis-Felipe Rodríguez, Salvador Cervantes, Francisco Cervantes, Félix Ramos - Science and Engineering Ethics, Sci. Eng. Ethics 2019 被引用: 145

  8. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    著者: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 被引用: 3,565

  9. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    著者: Francesco Passamonti, Francisco Cervantes, Alessandro M. Vannucchi, Enrica Morra, Elisa Rumi, Arturo Pereira, Paola Guglielmelli, Ester Pungolino, Marianna Caramella, Margherita Maffioli, Cristiana Pascutto, Mario Lazzarino, Mario Cazzola, Ayalew Tefferi - Blood 2009 被引用: 968

  10. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    著者: Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede H. Begna, Susan M. Schwager, Daniel Van Dyke, Curtis A. Hanson, Wenting Wu, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti, Ayalew Tefferi - Journal of Clinical Oncology 2010 被引用: 1,032

  11. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

    著者: Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver, Ronald Hoffman, Srđan Verstovšek, Ruben A. Mesa, Jean‐Jacques Kiladjian, Rȕdiger Hehlmann, Andreas Reiter, Francisco Cervantes, Claire Harrison, Mary Frances Mc Mullin, Hans Carl Hasselbalch, Steffen Koschmieder, Monia Marchetti, Andrea Bacigalupo, Guido Finazzi, Nicolaus Kröger, Martin Grießhammer, Gunnar Birgegård, Giovanni Barosi - Leukemia 2018 被引用: 552

  12. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

    著者: Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kawashima, Julia D. Maltzman, Jean‐Jacques Kiladjian, Srđan Verstovšek - The Lancet Haematology 2017 被引用: 315

  13. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

    著者: Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean‐Loup Demory, Giovanni Barosi, Elisa Rumi, Ayalew Tefferi - Blood 2008 被引用: 1,237

  14. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    著者: Ayalew Tefferi, Francisco Cervantes, Ruben A. Mesa, Francesco Passamonti, Srđan Verstovšek, Alessandro M. Vannucchi, Jason Gotlib, Brigitte Dupriez, Animesh Pardanani, Claire Harrison, Ronald Hoffman, Heinz Gisslinger, Nicolaus Kröger, Jüergen Thiele, Tiziano Barbui, Giovanni Barosi - Blood 2013 被引用: 379

  15. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

    著者: Francesco Passamonti, Toni Giorgino, Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jason Gotlib, Jean‐Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Domenica Caramazza, Michele Merli, Daniela Pietra, Rosario Casalone, Giada Rotunno, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi - Leukemia 2017 被引用: 334

  16. Mutations and prognosis in primary myelofibrosis

    著者: A. M. Vannucchi, T L Lasho, Paola Guglielmelli, Flavia Biamonte, Animesh Pardanani, Arturo Pereira, Christy M. Finke, J Score, Naseema Gangat, C Mannarelli, Rhett P. Ketterling, Giada Rotunno, R A Knudson, M C Susini, Rebecca R. Laborde, Ambra Spolverini, Alessandro Pancrazzi, Lisa Pieri, Rossella Manfredini, Enrico Tagliafico, Roberta Zini, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Daniela Pietra, Elisa Rumi, Francisco Cervantes, Giovanni Barosi, Mario Cazzola, Nicholas C.P. Cross, Ayalew Tefferi - Leukemia 2013 被引用: 746

  17. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    著者: Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Jean‐Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A.W. te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández‐Maraver, Heike L. Pahl, Martin Grießhammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Étienne, Jean‐Christophe Ianotto, Dana Ranta, Lydia Roy, Jean‐Yves Cahn, Claire Harrison, Deepti Radia, Pablo Muxí, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Björn Andréasson, Maria L Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegård, Ayalew Tefferi, Ruben A. Mesa - Journal of Clinical Oncology 2012 被引用: 458

  18. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    著者: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 被引用: 1,989

  19. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    著者: on behalf of the COMFORT-II Investigators, Claire Harrison, Alessandro M. Vannucchi, J-J Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, L. Knoops, Francisco Cervantes, Mark M. Jones, Kang Sun, Mari McQuitty, Viktoriya Stalbovskaya, P. Gopalakrishna, Tiziano Barbui - Leukemia 2016 被引用: 509

  20. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

    著者: Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Francisco Cervantes, Claire Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta - Journal of Hematology & Oncology 2017 被引用: 298

  21. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

    著者: Markus Pfirrmann, Michele Baccarani, Susanne Saußele, Joëlle Guilhot, Francisco Cervantes, G.J. Ossenkoppele, Verena Hoffmann, Fausto Castagnetti, Joerg Hasford, Rüdiger Hehlmann, Bengt Simonsson - Leukemia 2015 被引用: 300

  22. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

    著者: Thomas Ernst, Andrew Chase, Joannah Score, Claire Hidalgo-Curtis, Catherine Bryant, Amy V. Jones, Katherine Waghorn, Katerina Zoi, Fiona M. Ross, Andreas Reiter, Andreas Hochhaus, Hans G. Drexler, Andrew Duncombe, Francisco Cervantes, David Oscier, Jacqueline Boultwood, Francis Grand, Nicholas C.P. Cross - Nature Genetics 2010 被引用: 1,125

  23. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

    著者: Giovanni Barosi, Ruben A. Mesa, J. Thiele, Francisco Cervantes, Peter J. Campbell, Srđan Verstovšek, Brigitte Dupriez, Ross L. Levine, Francesco Passamonti, Jason Gotlib, John T. Reilly, Alessandro M. Vannucchi, Curtis A. Hanson, Lawrence A. Solberg, Attilio Orazi, Ayalew Tefferi - Leukemia 2007 被引用: 496

  24. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

    著者: Giovanni Barosi, Ruben A. Mesa, Guido Finazzi, Claire Harrison, Jean‐Jacques Kiladjian, Eva Lengfelder, Mary Frances McMullin, Francesco Passamonti, Alessandro M. Vannucchi, Carlos Besses, Heinz Gisslinger, Jan Samuelsson, Srđan Verstovšek, Ronald Hoffman, Animesh Pardanani, Francisco Cervantes, Ayalew Tefferi, Tiziano Barbui - Blood 2013 被引用: 289